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Summary. In our study, we investigate the possibilities of mathematical prediction of the poor 
outcome in patients with pneumonia associated with immune disorders on the background of 
oncohematological pathology. The study included 655 patients. It was identified predictors of the 
poor outcome of pneumonia and a mathematical model was created. We propose to use the scale 
forecast in clinical practice. It’s allow to optimize pneumonia treatment timely and reduce the 
mortality of patients and the number of hospitalization days.  
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Introduction. The 21st Century medicine is the medical knowledge and 
standards that emerged in evidence-based medicine. At the heart of it are randomized, 
so-called "blind" controlled studies. The application of mathematical methods with 
prediction elements in medical practice is also likely a modern tool of "evidence-
based medicine" [1]. The mathematical prognosis represents is a current interest in 
clinical practice today, because it is determines the main task of modern medicine - 
preventing diseases and timely optimizing the treatment. According to the 
dictionaries, the medical forecast is a prediction of "future diagnosis" [2]. There is a 
prognosis for the possibility of disease developing in medicine; it allows expecting 
some or other complications of the disease, death - as disease poor outcome or 
recovery [3]. The disease consequences forecast is based on the detection of 
pathological symptoms and syndromes in patients, the analysis of the regularities of 
the functioning of organs and systems. Determining the pneumonia severity using the 
scale of Fine M.J. et al., 1997 [4] is a well known method. Scoring systems on this 
scale are available in the Internet [http: // ncemi.org, www.emedhomom.com]. The 
main purpose of such forecast in medical practice is to plan medical measures, which 
include determination of treatment place (outpatient, general clinical or specialized 
department), and determination of treatment modification time (inclusion of new 
drugs, manipulations, etc.). The scale for determining treatment place for patients 
with community acquired pneumonia CURB-65/CRB-65, which estimated 5/4 
parameters (presence of 1 point, absence - 0 points) is widespread [5, 6]. The 
limitation for using these prognostic scales for patients with pneumonia associated 
with immune disorders is s ignoring, such important parameters for this category of 
patients, as the number of leukocytes, platelets, neutrophils. Thus, despite the large 
number of prognostic and diagnostic scales for determining treatment place, 
diagnosis, assessment of pneumonia severity, this issue is not resolved today, 
especially for patients with pneumonia on a background of oncohematological. 
Forecasting is a difficult task. To predict the disease, the doctor examines the patient, 
fixes the symptoms and syndromes, and based on their combination, causes and 
sequence of occurrence, clinical features of the disease, using of the other doctors 
experience (consultations, data literature) comes to the conclusion about the 
prediction the onset of a pathological process results with some degree of uncertainty. 
Moreover, the physician should take into account not only the patient’s general 
condition, his age, but also concomitant diseases, heredity, bad habits, living 
conditions, work activities for each patient. It is difficult to list all the factors which 
physician should analyze. The physician should choose the most appropriate 
treatment for the patient and think about the possible consequences after choosing 
different treatment places. Using the statistical methods in medicine gives physician 
the only correct solution, because mathematical methods can determine special 
disease factors – predictors, that affect to disease severity and determine the disease 
outcome [3].  
The urgency of the problem of diagnosis and treatment of pneumonia associated 
with immune disorders in patients on the background of oncohematological 
pathology is due to the high frequency of occurrence, lack of clinical manifestations, 
severe course, frequent complications and rapid development of poor outcome [7, 8]. 
Aim of the study: to create a mathematical model of pneumonia, associated 
with immune disorders poor outcome forecasting in patients on the background of 
oncohematological pathology for timely treatment optimization and determination the 
treatment place. 
Materials and methods. The study included 655 patients with pneumonia 
associated with immune disorders on the background of oncohematological 
pathology. A computer database was created based on 132 indicators of the clinical-
laboratory, anamnestic and immunological indicators results. The study was 
conducted in the haematological center “City Multidisciplinary Clinical Hospital 
№4”, Dnipro. The form and stage of oncohematological pathology and pneumonia 
diagnosis was determined according to the diagnostic standards [9, 10]. Data were 
analyzed using Microsoft Excel (Office Home Business 2KB4Y-6H9DB-BM47K-
749PV-PG3KT) add-on program AtteStat and software STATISTICA 6.1 
(StatSoftInc., Serial № AGAR909E415822FA). To describe the quantitative 
attributes median (Me) was used; to describe the signs variation - the interquartile 
scale (25%, 75%). To construct a predictive model, a pairwise and multiple 
regression analysis was used to calculate Spirman rank correlation coefficients (ρ), 
multiple comparisons were made with Bonferroni and Holm corrections [12]. A 
pairwise and multiple regression analysis, Spirman rank correlation coefficients (ρ) 
was used to construct a predictive model. Multiple comparisons were made with 
Bonferroni and Holm corrections [12]. The significance level was taken p <0,05 (5%) 
[11]. Factor analysis using the principal components method using the varimax of 
rotation was used to determine the predictors of an adverse outcome [12, 13]. Factor 
analysis with the principal components component with varimax rotation was used to 
determine the predictors of poor outcome [12, 13]. The results of our study revealed 
reliable connections between poor outcome of pneumonia associated with immune 
disorders on the background of oncohematological pathology and 61 quantitative and 
nominal indices. Indicators with statistically significant, moderate, and high 
correlation coefficients were selected to determine the predictors of the poor 
outcome. Indicators that characterize the patient's condition and cancer: erythrocyte 
(ρ = -0,61; p <0,001); platelets (ρ = -0.40; p <0.001); leukocyte (ρ = -0,63; p <0,001); 
HB (ρ = -0.48; p <0.001); the number of CT courses «8 and more» (ρ = 0,33; p 
<0,001), glycemia (ρ = 0,43; p <0,001), PS (ρ = 0,50; p <0,001). Indicators 
characterizing the pneumonia course: cough (ρ = 0,30; p <0,001), hemoptysis (ρ = 
0,36; p <0,001), ESR (ρ = 0,38; p <0,001), wet rattles (ρ = 0.48; p <0.001); breathing 
rate (BR) (ρ = 0,32; p <0,001) and the presence of Gp-causative agent (ρ = 0,48; p 
<0,001). Indicators characterizing the immune reactivity: the number of neutrophils 
(ρ = -0,34; p <0,001); CD 56,% (ρ = -0.86; p & lt; 0.001); CD56, G / L (ρ = -0.86; p 
<0.001); CD4 / CD8 (ρ = -0.62; p <0.001); lymphocytes,% (ρ = -0,58; p <0,001); 
CD4,% (ρ = -0.56; p <0.001); CD4, G / L (ρ = -0.49; p <0.001); T CD19,% (ρ = 0.53; 
p <0.001); B CD19, T / L (ρ = -0.46; p <0.001); HCT-stimulated test (ρ = -0.45; p 
<0.001); FA (ρ = -0,41; p <0,001); Ig G (ρ = -0.34; p <0.001); The HCT spontaneous 
test (ρ = -0.30; p <0.001), neutropenia degree (ρ = 0.37; p <0.001). 
Due to the mathematical models with AUC <0.7 do not have sufficient 
prognostic ability [13, 14], the analysis excluded indicators with smaller and close to 
this value of the area under the curve. Quantitative characteristics for calculating the 
odds ratio (OR) were translated into a binary format relative to the threshold 
forecasting level. Table. 1 show the clinical and laboratory parameters that influence 
for the survival possibility of patients with pneumonia, associated with immune 





The clinical and laboratory parameters that influence for the survival 
possibility 
Indicators 
(1 – yes, 0 – no) OR 95% CІ 
The proportion of 




Cough 4,99 3,14 - 7,93 68,01 91,39 <0,001 
CT courses ≥8 4,55 3,3 - 6,29 18,57 50,94 <0,001 
Hemoptysis 28,61 11,3 - 72,41 0,92 20,97 <0,001 
The presence of 
P. aeroginosa 5,45 3,91 - 7,6 15,99 50,94 <0,001 
Gp- pathogens 5,73 4,14 - 7,94 17,83 55,43 <0,001 
Glycemia 6,92 4,99 - 9,59 26,65 71,54 <0,001 
Neutropenia 3rd  
st. 12,45 8,13 - 19,08 6,07 44,57 <0,001 
Neutrophils 
≤1,4×109/л 6,26 4,51 - 8,69 17,65 57,30 <0,001 








93,23 6,57 72,73 <0,001 
Hb≤ 90 г/л 8,51 6,02 - 12,03 30,7 79,03 <0,001 
Erythrocytes 
≤ 2×1012/л 24,58 
16,64 - 
36,29 9,93 73,03 <0,001 
Platelets≤ 
60×109/л 6,5 4,7 - 9 19,67 61,42 <0,001 
Lymphocytes 
≤19,9 % 17,13 9,39 - 31,24 14,35 74,16 <0,001 
B CD19≤10,3 % 14,86 5,81 - 38,05 29,32 86,05 <0,001 
T CD19>58,29 % 33,87 12,57 - 91,22 20,99 90,0 <0,001 
СD4≤21,77 % 93,53 33,0 - 265,09 6,19 86,05 <0,001 
СD4/СD8≤1,09 112,07 25,72 - 488,25 15,46 95,35 <0,001 
CD56≤6,7 % 8787,0 170,74 - 452227,29 0 100,0 <0,001 
Ig G≤8,22 г/л 7,45 3,26 - 17,03 37,65 81,82 <0,001 
НСТ- stimulated 
test ≤26 % 10,48 4,78 - 22,99 13,87 62,79 <0,001 
Note. * - Differences between groups according to Pearson's χ2 criterion 
 
Results of simple logistic regression analysis showed that probability of 
pneumonia poor outcome depends on the state of the patient’s immune response: 
CD4≤21.77% (OR 93.53 [95% CI 33.0-265.09]; T CD19> 58.29 % (OR 33.87 [95% 
CI 12.57-91.22]); CD56≤6.7% (OR 8787.0 [95% CI 170.74-452227.29]); CD4 / 
CD8≤1 , 09 (OR 112.07 [95% CI 25.72-488.25]); HCT-stimulated test ≤26% (OR 
10.48 [95% CI 4.78-22.99]). The pneumonia poor outcome forecasting using the 
indicators that characterized the pneumonia severity: the number of leukocytes ≥2,98 
× 109 / l (OR 37,93 [95% CI 15,43-93,23]), hemoptysis (OR 28,61 [95 % CI 11.3-
72.41]), wet wheat (OR 28.1 [95% CI 14.72-53.65]); cough (OR 4.99 [95% CI 3.14-
7.93]); Gg- pathogens (OR 5.73 [95% CI 4.14-7.94]); the presence of P. aeroginosa 
(OR 5.45 [95% CI 3.91-7.6]). pneumonia poor outcome forecasting using the 
indicators that characterized the oncological disease: hemoglobin ≤90 g / l (OR 8.51 
[95% CI 6.02-12.03]); erythrocytes ≤2 × 1012 / l (OR 24.58 [95% CI 16.64-36.29]); 
platelets <60 × 109 / l (OR 6.6 [95% CI 4.7-9]); lymphocytes ≤19.9% (HS 17.13 
[95% CI 9.39-31.24]); the number of CT courses “8 and more” (OR 4.55 [95% CI 
3.3-6.29]) glycemia (OR 6.92 [95% CI 4.99-9.59]); neutrophils  ≤1.4 × 109 / l (OR 
6.62 [95% CI 4.51-8.69]).  
The relationship between "died" or "survived" was analyzed using a logistic 
regression model with a step-by-step predictors inclusion [13, 14]. The logistic 
equation was taken as the basis for the predictive model development:  
у=exp(b0+b1*x1+...+bn*xn)/[1+exp(b0+b1*x1+...+bn*xn)]                  (1), 
where, y - the result (in our study - the pneumonia poor outcome forecasting 
(POF); b0 - free part of the regression equation; b1 -bn - regression coefficients; x1-xn - 
predictor variables. 
If the calculated probability of pneumonia poor outcome is less than 0.5 - it is 
possible the event will not occur (the patient will not die); if probability more than 
0.5 - the pneumonia poor outcome is likely happen.  
Tabl. 2. shows predictors of the pneumonia associated with immune disorders 




Predictors of the pneumonia associated with immune disorders on the 
background of oncohematological pathology poor outcome identify by logistic 
regression analysis 
Forecasting variables Regression 
coefficient β 
Standard error 
of β coefficient χ
2 Wald p-value  
Equation free member -19,714    
Gg- pathogens (х1) 2,840 2,158 4,643 0,031 
Erythrocytes (х2) -4,404 1,229 6,887 0,009 
СD4/СD8 (х3) -4,298 2,945 5,905 0,015 
Leukocytes (х4) -1,327 0,576 3,856 0,050 
Neutropenia 3rd  st (х5) 19,354 4,167 12,108 0,001 
Ig G (х6) -0,154 0,174 8,661 0,003 
Хі-square χ2=188,36 (p<0,001) 
Concordance percentage 99,44 % 
Hosmer-Lemesh Test 0,220 (р=0,997) 
 
Nominal indicators were entered into the equation in form: 1 - present, 0 - 
absent. Quantitative indicators - in commonly accepted units. 
According the results of our study the mathematical model of the pneumonia 
associated with immune disorders on the background of oncohematological 
pathology poor outcome  is:  
POF=exp(-19,714+2,840*x1-4,404*x2-4,298*x3-1,327*x4+19,354*x5-
0,154*x6)/[1+exp(-19,714+2,840*x1-4,404*x2-4,298*x3-1,327*x4+19,354*x5- 
0,154*x6)]                                 (2), 
 
where, POF - the result that changes from 1 (died) to 0 (alive); b0 = -19,714 - 
regression equation free member; x1 - presence of Gp- pathogens; x2 - erythrocytes; 
x3 - immunoregulatory index (СD4 / СD8); x4 - leukocytes; x5 - neutropenia 3 st .; x6 
– IgG.  
Thus, if the POF for a particular patient is more than 0.5 - it is possible to make 
a prediction of high risk of death; if it less than 0.5 - it is possible to consider the 
prognosis is favorable for the patient. 
 
Fig. 1. Operational characteristics of the mathematical model of the 
pneumonia associated with immune disorders on the background of 
oncohematological pathology poor outcome forecasting determined using ROC 
analysis. 
 
The POF equation estimating the predictive ability by Xi-square (χ2) showed its 
adequacy: χ2 = 188.36 (p <0.001); the proportion of the correct prediction of patient 
belongs of to one or another group amounted to 99.44; according to the qualitative 
evaluate - excellent. Thus, the POF mathematical model has excellent operational 
characteristics: sensitivity - 97,67%, specificity - 100,0%, area under the ROC curve - 
0,999 (Fig. 1). 
We have developed a predicting scale for risk of pneumonia associated with 
immune disorders poor outcome. It was determined if the point lower than 0.278 - the 
risk of death is low. In such cases it is possible to recommend ambulatory pneumonia 
treatment or treat the pneumonia in therapeutic department. When the point is from 
0.278 to 0.500 - the risk of death is high. In such cases it is possible to recommend to 
treat the pneumonia in a specialized hematological department. When the point is 
above 0,500 - the risk of death is very high. In such cases it is necessary to treat 
pneumonia in an intensive care unit and to optimize the treatment. Long-term results 
can be reduced patients mortality and decrease the number of hospitalization days. 
Conclusions. The results of our study showed that probability of pneumonia 
associated with immune disorders poor outcome in patients on the background of 
oncohematological pathology most depends on patient’s immune reactivity; 
moreover, a poor outcome depends on indicators that characterized pneumonia 
severity and indicators that characterized the main oncohematological disease course. 
We identified independent predictors of pneumonia poor outcome and created 
mathematical model of pneumonia poor outcome forecasting. Mathematical model 
has excellent operational characteristics according to the ROC analysis. 
1. Predictors of pneumonia associated with immune disorders poor outcome in 
patients with oncohematological pathology were detected in our study. It are 
indicators that characterized the pneumonia severity: the number of leukocytes, 
hemoptysis, wet wheezing, cough, Gp- pathogens (OR 5.73 [95% CI 4.14-7.94]) and 
P. aeroginosa (OR 5.45 [95% CI 3.91-7.6]; indicators that characterize the patient and 
oncohematological disease: age (ρ = -0.25, p <0.001), the oncohematological form (ρ 
= 0,29, p <0,001); the HT courses number (from 8) (ρ = 0.33, p <0.001), anemia (ρ = 
0.61, p <0.001); the presence of neutropenia (ρ = 0.46, p <0.001); indicators of 
immune reactivity: (CD4≤21.77% (OR 93.53 [95% CI 33.0-265.09]; T CD19> 
58.29% (OR 33.87 [95% CI 12.57-91, 22]), CD56≤6.7% (OR 8787.0 [95% CI 
170.74-452227.29]); II ≤ 1.09 (OR 112.07 [95% CI 25.72-488.25 ]); HCT-test sp. ≤ 
26% (OR 10.48 [95% CI 4.78-22.99]). 
2. As a result of our study, we created the mathematical model of pneumonia 
associated with immune disorders poor outcome forecasting on the background of 
oncohematological pathology.  
POF=exp(-19,714+2,840*x1-4,404*x2-4,298*x3-1,327*x4+19,354*x5-0,154*x6)/ 
[1+exp(-19,714+2,840*x1-4,404*x2-4,298*x3-1,327*x4+19,354*x5-0,154*x6)], 
where, POF – poor outcome forecasting; b0 = -19,714 - regression equation free 
member; x1, x2, x3, x4, x5, x6 - poor outcome forecasting predictors. 
3. We have developed a predicting scale for risk of pneumonia associated with 
immune disorders poor outcome. It was determined if the point lower than 0.278 - the 
death risk is low (should to recommend ambulatory treatment or treating in 
therapeutic department); 0.278 to 0.500 - the death risk is high (should to recommend 
to treat pneumonia in a specialized hematological department); point is above 0,500 - 
the death risk  is very high (should to treat pneumonia in an intensive care unit).  
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Анотація. В роботі розглядаються можливості математичного прогнозування у 
вирішення актуального питання пульмонології та гематології, а саме, прогнозування 
настання летального результату у хворих на пневмонії, асоційованих з порушеннями 
імунітету на фоні онкогематологічної патології. В дослідженні на достатній кількості 
(655 хворих) матеріалу визначені предиктори настання летального результату пневмонії 
та створена математична модель прогнозу у хворих на пневмонії, асоційованих з 
порушеннями імунітету на фоні онкогематологічної патології. Використання в клінічній 
практиці запропонованої шкали прогнозу дозволить своєчасно оптимізувати лікування 
пневмоній, асоційованих з порушеннями імунітету на фоні онкогематологічної патології та 
знизити летальність хворих і кількість днів госпіталізації з цього приводу.  
Ключові слова: математична модель прогнозу, пневмонія, порушення імунітету, 
онкогематологічна патологія, несприятливий результат 
Аннотация. В работе рассматриваются возможности математического 
прогнозирования в решении актуального вопроса пульмонологии и гематологии, а именно, 
прогнозирование наступления летального исхода у больных пневмониями, ассоциированых с 
нарушениями иммунитета на фоне онкогематологической патологии. В исследовании на 
достаточном количестве материала (655 больных) определены предиктори наступления 
летального исхода пневмонии и создана математическая модель прогноза у больных с 
пневмониями, ассоциированых с нарушениями иммунитета на фоне онкогематологической 
патологии. Использование в клинической практике предложенной шкалы прогноза позволит 
своевременно оптимизировать лечение пневмоний, ассоциированых с нарушениями 
иммунитета на фоне онкогематологической патологии и снизить летальность больных и 
количество дней госпитализации по этому поводу. 
Ключевые слова: математическая модель прогноза, пневмония, нарушения 
иммунитета, онкогематологическая патология, летальный сход  
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